We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This document explains the Down’s syndrome screening quality assurance support service (DQASS) and how to use it.
Volume 10 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
The management, surveillance and epidemiology of carbapenem resistance.
Information about the EU Regulations and their implementation in Northern Ireland
Find out about the symptoms of COVID-19, what to do if you or your child has them and when to get medical help.
Optimise your API service level indicators based on your user needs.
We remind healthcare professionals that accidental use of glucose-containing solutions as flush fluid for arterial lines may contaminate blood samples and result in falsely high glucose readings. This may lead to inappropriate insulin administration and subsequent hypoglycaemia. Healthcare professionals should...
Falsified, potentially harmful Ozempic▼ and Saxenda products have been found in the UK.
Information on ionising radiation damage and cancer risks.
Information for pregnant women to understand what it means to be a haemoglobin D carrier.
Further measures to be introduced to ensure patients who are prescribed montelukast for the treatment of asthma are informed of the risk of neuropsychiatric reactions
Notifications about suspected infectious diseases, collected by the UK Health Security Agency (UKHSA).
Guidance for healthcare professionals covers the use, management and safety of in vitro diagnostic (IVD) devices, including blood glucose meters.
A patient alert card is being introduced for men taking finasteride to help raise awareness of the risk of psychiatric side effects and sexual dysfunction, including the potential for sexual dysfunction to persist after treatment has stopped. Healthcare professionals are...
Data sources of numbers relating to the coronavirus pandemic in the UK.
The MHRA will introduce a patient alert card to increase awareness among men taking finasteride about potential psychiatric and sexual side effects
UK Health Security Agency's laboratories provide a comprehensive range of microbiological tests and services.
Data on the real-world efficacy of the COVID-19 vaccines.
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.